HK Stock MarketDetailed Quotes

00460 SIHUAN PHARM

Watchlist
  • 0.550
  • -0.010-1.79%
Trading Jul 19 13:19 CST
5.13BMarket Cap-91666P/E (TTM)

About SIHUAN PHARM Company

Sihuan Pharmaceutical Holding Group Co., Ltd. (“Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries is the “Group”) (stock code: 00460.HK) was founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010. It is an international medical, aesthetic and biopharmaceutical enterprise with an independent and leading independent production, research and development (“R&D”) technology platform led by innovation and a mature and excellent sales system. Sihuan Pharmaceutical focuses on high-growth treatment fields such as medical aesthetics, oncology, metabolism, diabetes, cardiovascular, modern traditional Chinese medicine, and industrial marijuana, and has always adhered to the overall strategic goal of “adhering to the full speed promotion of Sihuan Medical Aesthetics and Biopharmaceuticals two-wheel drive strategy” to build a leading medical, aesthetic and biopharmaceutical enterprise in China.

Company Profile

Symbol00460
Company NameSIHUAN PHARM
ISINBMG8162K1137
Listing DateOct 28, 2010
Issue Price4.60
Shares Offered1.25B share(s)
FoundedApr 26, 2006
Registered AddressBermuda
Chairmanfengsheng che
Secretaryyanlinglijianwei chen
Audit InstitutionErnst & Young
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeClarendon House 2 Church Street Hamilton HM 11 Bermuda
Head Office and Principal Place of BusinessRoom 4905, Convention Plaza Office Tower, 1 Harbour Road, Wanchai, Hong Kong
Fiscal Year Ends12-31
Employees2872
MarketHong Kong motherboard
Phone(010)57693700;(852)36283911
Fax(010)85867669-100
Emailinfo@jsdmss.com
Business Sihuan Pharmaceutical Holding Group Co., Ltd. is an investment holding company mainly engaged in R&D, manufacturing and sales of pharmaceutical products and medical and aesthetic products. The company operates its business through three divisions. The Medical and Aesthetic Products segment includes fillers, contouring, support, supplements, optoelectronic equipment, body sculpting, skin care, and others, as well as providing comprehensive solutions for light medicine and beauty. The Innovative Drugs and Other Drugs Division develops and commercializes innovative drugs in diseases such as diabetes, breast cancer, digestion, tumors, and non-alcoholic steatohepatitis. The Generic Drugs Division is engaged in the production and sale of generic drugs, including Clarion. The company operates in domestic and foreign markets.

Company Executives

  • Name
  • Position
  • Salary
  • fengsheng che
  • presidencies,Executive Director,Remuneration Committee Members
  • --
  • jionglong zhang
  • Executive Director
  • --
  • weicheng guo
  • vice-chairman,CEO,Executive Director,Nomination Committee Members,Member of the Risk Management Committee
  • --
  • guili mou
  • Executive Director,Deputy Chief Executive,chief financial officer,Risk Committee Member Co-Chairman
  • --
  • yanling chen
  • Executive Director,Joint Company Secretary,Co-Chairman of the Risk Committee,Authorized Representative
  • --
  • huaguang ceng
  • Independent Non-Executive Director,Chairman of the Audit Committee,Nomination Committee Members,Member of the Risk Management Committee,Remuneration Committee Members
  • --
  • xun zhu
  • Independent Non-Executive Director,Remuneration Committee Chairman,Audit Committee Members,Nomination Committee Members
  • --
  • guan wang
  • Independent Non-Executive Director,Chairman of the Nomination Committee,Audit Committee Members,Remuneration Committee Members
  • 202.00K
  • jianwei li
  • Joint Company Secretary,Authorized Representative
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg